Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-03-17

FDA Approved: ALYFTREK — Supplemental Application (Vertex Pharmaceuticals Incorporated)

View source ↗

Summary

FDA approved a supplemental application for ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR) from Vertex Pharmaceuticals Incorporated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)

Snippet

SUPPL AP for ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)